IL-17 A and IL-17 F single nucleotide polymorphisms and acute myeloid leukemia susceptibility and response to induction therapy in Egypt

IL-17 is a proinflammatory cytokine family produced by Th-17 cells and has been found to be implicated in the pathophysiology of many cancers including acute myeloid leukemia (AML). Since single nucleotide polymorphism (SNP) alters the genetic functions and cancer susceptibility, we studied SNPs in two members of IL-17 family, IL-17A (rs2275913; G-197A) and IL-17F (rs763780; A7488G) which are the most common loci associated with IL-17 activity and cancer risk, and correlated the results to AML susceptibility and response to therapy. The study included 200 participants; 100 de novo AML patients and 100 age and sex matched healthy control subjects. SNPs in IL-17A (rs2275913; G-197A) and IL-17F (rs763780; A7488G) were studied using restriction fragment length polymorphism polymerase chain reaction (PCR-RFLP). IL-17A homozygote mutation was more frequent in AML patients compared to control subjects (P = 0.034) and conferred 2.8 fold increased risk of AML (OR = 2.755 [95% CI: 1.078–7.042]). While IL-17F mutation showed no correlation with acute myeloid leukemia susceptibility. Also neither IL-17 A nor IL 17-F mutation showed significant correlation to therapy outcome. In conclusion, IL-17 A homozygote mutation may be associated with AML susceptibility.